Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prognostic biomarkers in diffuse large B-cell lymphoma.

Izidore S Lossos1, Daniel Morgensztern

  • 1Department of Medicine, Division of Hematology/Oncology, University of Miami/Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA. ilossos@med.miami.edu

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|January 19, 2006
PubMed
Summary

Diffuse large B-cell lymphoma (DLBCL) is heterogeneous, with outcomes varying despite the International Prognostic Index. Novel molecular biomarkers show promise for improved prediction and personalized therapy in DLBCL patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

Nature medicine·2026
Same author

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma.

American journal of hematology·2026
Same author

Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma.

American journal of hematology·2026
Same author

SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

Nature medicine·2026
Same author

Response to: "Refining Combined-Modality Therapy and Charting the Future of Primary Vitreoretinal Lymphoma".

American journal of hematology·2026
Same author

Risk of intensive care unit admission after immune checkpoint inhibitor use in cancer.

Seminars in oncology·2026

Area of Science:

  • Oncology
  • Hematology
  • Genetics

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma, with less than 50% cure rates using conventional chemotherapy.
  • Patient outcomes in DLBCL are highly variable, indicating significant tumor heterogeneity beyond the International Prognostic Index (IPI).

Purpose of the Study:

  • To review recent advances in prognostic biomarkers for DLBCL.
  • To discuss the potential of these biomarkers for risk-adjusted therapy in clinical practice.

Main Methods:

  • Review of literature on genetic alterations and protein expression in DLBCL.
  • Analysis of DNA microarrays and tissue array technologies for biomarker discovery.
  • Evaluation of novel diagnostic tools for outcome prediction.

Related Experiment Videos

Main Results:

  • Identification of novel molecular markers that predict DLBCL patient outcomes independently of clinical variables.
  • DNA microarrays and tissue arrays enhance understanding of lymphoma biology and diagnostic tools.

Conclusions:

  • Significant heterogeneity exists within DLBCL, necessitating improved prognostic models.
  • Emerging biomarkers offer potential for more accurate outcome prediction and personalized, risk-adjusted therapy in DLBCL.